Biotech Co.* |
Pharma Co. (Country) |
Product |
Terms/Details (Date) |
Alba |
Peptisyntha |
Peptisyntha will lead the manufacturing process development of Alba's upcoming products |
Details on the deal were not disclosed (8/20) |
AltaRex |
Dompe International SA (Switzerland) |
Dompe got exclusive rights to distribute OvaRex MAb in certain areas, and rights of first refusal to other cancer antibodies |
The rights and option cover Italy, Spain, Portugal, Hungary, Poland, Czech Republic, Switzerland, Austria and other Eastern European countries; they entered a memorandum of understanding on this deal in 2000 (7/6) |
Caliper Life |
Sigma-Aldrich Corp. |
Deal to develop and co-market a series of automated turnkey solutions |
The products would have applications in genomics, proteomics and drug discovery (8/16) |
Cangene |
Baxter Healthcare Corp. |
Baxter will take over U.S. distribution of Cangene's WinRho SDF in March 2005 |
Baxter will replace Nabi Biopharmaceuticals as distributor; a Baxter affiliate already distributes the product in Europe (7/20) |
Chiral Quest |
DSM Pharma Chemicals (the Netherlands) |
Deal to further develop applications of CQ's catalytic products and technology |
DSM got a license to use the technology, for use in manufacturing intermediates in the life sciences sector (7/14) |
Chiral Quest Inc. (OTC BB: CQST) |
Sigma-Aldrich Corp. |
Deal under which Sigma will distribute Chiral Quest ligands |
The deal covers the Binaphane, C3-Tune-Phos, TangPhos and Binapine ligands; terms were not disclosed (7/13) |
Codexis Inc.* |
Lonza Group Ltd. (Switzerland) |
Lonza will use the Codexis biocatalytic process for synthesis of a chiral pharmaceutical compound |
Codexis will receive license fees and royalties, and sell biocatalysts to Lonza for use in the production process, which will involve Codexis' directed molecular evolution platform (7/27) |
CombiMatrix |
Strand Genomics Pvt. Ltd. (India) |
Co-marketing deal for avadis, a data- analysis software tool for microarray gene expression |
Terms on the deal covering CombiMatrix's avadis were not disclosed (7/9) |
Connetics Corp. (CNCT) |
Hoffmann-La Roche Inc. |
Deal under which Connetics can sell Soriatane to an unnamed distributor for exportation to select international markets |
Connetics will pay a royalty to Roche on Soriatane sales to the distributor; Connetics acquired rights to the oral psoriasis drug from Roche earlier this year (7/28) |
Corixa Corp. (CRXA) |
GlaxoSmithKline Biologicals (Belgium) |
Deal through 2012 covering manufacturing and supply of Corixa's adjuvant, monophos-phoryl lipid A, or MPL |
Corixa gets a multimillion-dollar up-front licensing fee and supply payments, as well as royalties on sales of any GSK vaccine containing MPL adjuvant; a provision allows Corixa to repay a $5M loan in stock rather than cash (7/26) |
EntreMed Inc. |
Elan Drug Delivery Inc. (unit of Elan Corp. plc) |
Elan will reformulate and manufacture EntreMed's Panzem in an oral liquid form |
Elan will use its NanoCrystal technology in the deal, terms of which were not disclosed (7/13) |
Generex |
PharmaBrand SA (Ecuador) |
Expanded joint venture to include Farmacid SA, an Ecuadorian manufacturer of pharmaceutical products that's a PharmaBrand affiliate |
Their venture now will include a turnkey filling operation for Oralin as a first step toward global commercialization of the product; Generex gets a 25% equity interest in the entire manufacturing facility (8/26) |
Inyx |
AstraZeneca plc (UK) |
Inyx will help develop a version of AstraZeneca's Pulmicort asthma spray for European markets |
The three and a half year contract is valued at $6.5M per year to Inyx, which will develop a non-ozone-depleting hydrofluoralkane version of the product (6/29) |
MGI Pharma |
Alpharma Inc. |
MGI will promote Alpharma's sustained- release morphine product, Kadia, in the U.S. for pain associated with cancer |
Intitially in the three-year deal they will share profits from MGI sales; further terms were not disclosed (7/14) |
Microbix |
Undisclosed vaccine producer |
Microbix's technology for enhancing virus yield |
Companies entered exclusive negotiation period; Microbix gets monthly payments during the review, and $1M if it delivers a fourfold yield improvement; it then could get milestone and royalty payments (6/18) |
Molecular Insight Pharmaceuticals Inc.* |
MDS Nordion (unit of MDS Inc.; Canada) |
MDS will manufacture BMIPP, Molecular Insight's molecular imaging product that's in Phase II trials for detecting ischemia |
The product is labeled with MDS' iodine-123; terms of the deal were not disclosed (6/16) |
MWG Biotech AG (Germany;FSE:NWUG) |
Unnamed company |
Global supply contract for oligonucleotides |
MWG expects annual revenue of €1M from the deal with the pharmaceutical company; details were not disclosed (7/29) |
NeoPharm |
Nippon Genetics Co. Ltd. (Japan) |
Nonexclusive worldwide distribution and marketing agreement for Neopharm's NeoPhectin and NeoPhectin-AT |
Nippon Genetics will market and promote the transfection reagents to its customers worldwide; terms were not disclosed (8/5) |
NPE Systems Inc.* |
Beckman Coulter Inc. |
Exclusive licensing and development agreement on NPE's flow-based cellular analysis systems |
Beckman Coulter will integrate NPE's Quanta family of products into its Cell Lab suite of cellular analysis solutions; terms were not disclosed (8/11) |
Qiagen NV |
Novartis Pharma |
Qiagen will be the global supplier for products and services related to nucleic acids |
Terms of the deal were not disclosed (8/2) |
Qiagen NV (the Netherlands; QGENF) |
AstraZeneca plc (UK) |
Qiagen will supply siRNA molecules to AstraZeneca |
Qiagen will be the preferred supplier for siRNA products used in gene silencing; terms were not disclosed (6/30) |
Transkaryotic Therapies Inc. (TKTX) |
Lonza Biologics plc (UK) |
Lonza will manufacture TKT's Dynepo, an erythropoietin product |
Terms were not disclosed; TKT looks to have the product on the market in Europe in late 2005 or early 2006 (8/3) |
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
FSE = Frankfurt Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | |||
